CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 16 enrolled
Drug / intervention
Sitagliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00657280
NCT00657280Early Ph 1Completed
CompareCT.gov

Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure

Stanford University·interventional·Posted Apr 14, 2008·Updated Dec 5, 2014

In Brief

A Early Phase 1 clinical trial evaluating Sitagliptin for Heart Failure, Congestive. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Congestive
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Early Ph 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 14, 2008
Enrollment StartApr 1, 2008
Primary CompletionFeb 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.2 years ago

Interventions

Sitagliptindrug

No one is blinded to the treatments.